Yes, methotrexate can cause anemia, and it does so through two distinct mechanisms that operate on different timelines. The drug blocks dihydrofolate reductase, starving rapidly dividing bone marrow cells of the folate they need to build red blood cells, which can produce macrocytic anemia over weeks to months. Separately, at high or sustained exposure, methotrexate can suppress bone marrow production directly, dropping hemoglobin within 7 to 14 days. Most anemia on low-dose weekly therapy is mild and folate-responsive, but roughly 3 to 5 percent of patients develop clinically significant drops that require dose adjustment or rescue with leucovorin.
How Methotrexate Depletes Red Blood Cells
Methotrexate works by inhibiting dihydrofolate reductase (DHFR), the enzyme that converts dietary folate into its active tetrahydrofolate form. Tetrahydrofolate is the raw material for thymidine and purine synthesis, the building blocks of DNA. Red blood cell precursors in the bone marrow divide faster than almost any other tissue in the adult body, so they are disproportionately exposed when folate recycling stalls.
The consequence is ineffective erythropoiesis. The marrow keeps producing precursor cells, but they cannot complete DNA synthesis and division normally, so they enlarge and die before maturing. The cells that do escape into circulation are oversized, which is why the classic blood picture is macrocytic anemia with an elevated mean corpuscular volume (MCV), typically above 100 femtoliters. This is biochemically identical to the megaloblastic anemia of severe folate or B12 deficiency.
In plain terms: methotrexate jams the folate recycling line, and red cells are the factory product most sensitive to the jam.
A second, faster mechanism exists. Methotrexate polyglutamates accumulate inside cells and inhibit additional folate-dependent enzymes, and at higher intracellular concentrations the drug suppresses marrow proliferation directly rather than only through folate starvation. This is the mechanism behind the acute hemoglobin drop seen after high-dose regimens, and it is the reason leucovorin rescue exists.
Two Anemias, Two Timelines
Clinicians distinguish the slow folate-deficiency pattern from the fast direct-suppression pattern because the management differs. The table below reconciles the mechanisms, typical lab findings, and expected time to onset.
| Feature | Folate-deficiency (megaloblastic) pattern | Direct marrow suppression pattern |
|---|---|---|
| Primary trigger | Cumulative DHFR blockade on weekly low-dose therapy | High-dose IV, overdose, or renal impairment with drug accumulation |
| Typical MCV | Elevated, often 100-110 fL | Normal or low |
| Reticulocyte count | Low | Low |
| Earliest hemoglobin drop | 4 to 8 weeks | 7 to 14 days |
| Folate level | Low serum folate common | May be normal |
| Responsive to folic acid | Usually yes | Not reliably; leucovorin needed |
| Typical setting | Rheumatoid arthritis, psoriasis on 10-25 mg weekly | Oncology regimens, acute overdose |
The two patterns can coexist. A patient on weekly methotrexate who also has chronic kidney disease may accumulate drug and develop the fast pattern on top of the slow one, which is why renal function monitoring matters as much as folate supplementation.
How Common Is Anemia on Methotrexate?
Frequency depends entirely on dose, route, and duration, and the published ranges are wide. In low-dose weekly methotrexate for rheumatoid arthritis, large cohort studies place clinically significant anemia at roughly 3 to 5 percent of patients per year, with mild falls in hemoglobin far more common and often attributed to the underlying inflammatory disease rather than the drug. In psoriasis cohorts on similar doses, macrocytosis without anemia is seen in up to 30 percent of patients, an early signal that folate status is drifting.
High-dose methotrexate tells a different story. When regimens exceed 500 mg per square meter, cytopenias including anemia occur in a substantial minority of patients, and grade 3 or 4 hematologic toxicity is reported in roughly 10 to 20 percent of high-dose courses depending on leucovorin rescue protocols and renal clearance. Per the 2020 American College of Rheumatology guideline for rheumatoid arthritis, complete blood counts should be checked every 2 to 4 weeks during the first months of low-dose therapy, then every 3 to 6 months once stable, precisely because early anemia is common and silent.
The dose distinction is the single most useful number to hold onto. Below 25 mg weekly, anemia is usually slow and folate-related; above 500 mg per square meter, it can be rapid and dangerous.
Risk Factors That Change the Math
Age above 65 roughly doubles the risk of significant anemia on methotrexate in most rheumatology cohorts, largely because renal clearance declines with age even when serum creatinine looks normal. Renal impairment is the dominant modifiable risk: methotrexate is cleared 80 to 90 percent unchanged by the kidney, so a fall in glomerular filtration rate from 90 to 45 mL/min can double drug exposure and transform a stable dose into a toxic one.
Other factors that shift risk upward include low baseline folate, alcohol use, concurrent trimethoprim or sulfamethoxazole (which block the same folate pathway), proton pump inhibitors at high dose, and pre-existing macrocytosis. Obesity matters less than expected because dosing in rheumatology is typically fixed rather than weight-based, but oncology dosing per body surface area does raise absolute exposure.
A non-obvious point: a normal MCV does not rule out methotrexate anemia. When folate deficiency and iron deficiency coexist, the MCV can sit in the normal range because the two abnormalities cancel each other's effect on cell size. The marrow is still megaloblastic; the average cell volume simply hides it. In that setting, a low reticulocyte count and a rising red cell distribution width are better early clues than MCV alone.
Correcting a Common Misconception
The most widespread error is the belief that folic acid supplementation makes methotrexate anemia impossible. It reduces risk substantially but does not eliminate it. Standard practice pairs methotrexate with 1 mg of folic acid daily or 5 mg once weekly (not on the methotrexate day), and this cuts mucosal and hematologic side effects meaningfully. However, folic acid cannot rescue a patient whose marrow is being suppressed by accumulated methotrexate polyglutamates, and it does not correct the direct suppression pattern. Leucovorin, a reduced folate that bypasses the DHFR block, is the rescue agent for that scenario.
A second misconception is that anemia on methotrexate always means the drug must stop. In practice, mild macrocytic anemia with a normal reticulocyte response often resolves with folate optimization and dose review. The decision to hold the drug hinges on the rate of fall, the absolute hemoglobin, and whether other cell lines are affected.
When Anemia Becomes an Emergency
Most methotrexate anemia is indolent, but a subset is a hematologic emergency. The red flags below warrant same-day blood counts and clinician contact, not watchful waiting.
- Hemoglobin below 8 g/dL, or a drop of more than 2 g/dL in under two weeks
- Any concurrent drop in white cells or platelets (pancytopenia suggests marrow suppression)
- Mouth ulcers, fever, or sore throat alongside fatigue (signals mucositis and cytopenia)
- Reduced urine output or a rising creatinine (suggests drug accumulation)
- New shortness of breath, chest pain, or fainting
- Bruising or bleeding that was not present before
Pancytopenia on methotrexate is uncommon on low-dose therapy but is the pattern most associated with serious harm, and it typically emerges when renal function has quietly worsened.
What to Actually Do
Concrete actions reduce risk more reliably than any single lab value. Get a baseline complete blood count and folate level before starting, then repeat counts at 2 to 4 weeks, 8 weeks, and every 3 to 6 months once stable. Take folic acid as prescribed, and confirm the dose and timing with the prescriber rather than self-adjusting. Report new fatigue, breathlessness, or mouth sores promptly rather than waiting for the next scheduled visit.
Review every new medication for folate antagonism, especially antibiotics in the trimethoprim-sulfamethoxazole family. Keep alcohol modest and stay hydrated, because dehydration concentrates the drug. If creatinine rises or the estimated glomerular filtration rate falls below 45 mL/min, ask whether the methotrexate dose needs reduction before anemia appears. If hemoglobin is falling but MCV is normal, ask for a reticulocyte count and iron studies rather than assuming iron deficiency alone.
Limits of the Evidence
Most frequency estimates come from observational rheumatology and dermatology cohorts, not randomized trials, so the true incidence is imprecise and confounded by the underlying disease. The 3 to 5 percent figure reflects clinically recognized anemia, not every subclinical hemoglobin dip, and different studies use different thresholds. The high-dose oncology numbers vary widely by regimen, and leucovorin protocols have changed over decades, making historical comparisons unreliable. The mechanistic story of DHFR blockade is well established, but the relative contribution of direct marrow suppression versus folate starvation at any given dose remains partly inferred rather than precisely measured. What is certain is that anemia is a real, monitorable, and largely manageable risk, and that regular blood counts plus folate supplementation catch most cases before they become serious.